Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Privately-held US firm Ossianix has announced a strategic research collaboration with Danish central nervous system drug specialist Lundbeck to develop novel biopharmaceuticals for very difficult CNS drug targets. 7 January 2014
US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out payable to the former shareholders of Germany’s Fumapharm AG for $510 million in cash. 6 January 2014
Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA, for approval of Viibryd (vilazodone) for major depressive disorders and Colobreathe (colistimethate sodium) to treat lung infections in patients with cystic fibrosis. 6 January 2014
Anglo-Swedish drug major AstraZeneca has entered into a two-year research collaboration with the USA-based Lieber Institute for Brain Development to use genetics and stem cell biology to discover new drugs for neuropsychiatric and neurodevelopmental disorders such as autism and schizophrenia. 4 January 2014
The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will be available to eligible patients by prescription in the USA beginning January 6, something of a delay given that the drug was approved by the Food and Drug Administration in October 2012. 2 January 2014
There was a significant disappointment this morning for French drug major Sanofi, when it revealed that its US biotech subsidiary Genzyme had received a Complete Response Letter from the US Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. 30 December 2013
Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia therapy by 2016, predicts independent analyst firm Datamonitor Healthcare. 29 December 2013
The European Commission has granted marketing authorization for Danish CNS specialist Lundbeck’s Brintellix (vortioxetine) for the treatment of adults with major depressive episodes, commonly referred to as depression. 29 December 2013
The Alzheimer’s Disease (AD) market will increase slightly from $3.6 billion in 2012 to $3.8 billion in 2019, according to business intelligence provider GBI Research. 27 December 2013
Orion Corp has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion's investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer's disease, including a clinical phase compound ORM-12741. 20 December 2013
French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice President in charge of Human Resources of the Ipsen group in place of Etienne de Blois. 19 December 2013
Shares of US biopharma drug developer Targacept tanked nearly 33% to $4 in pre-market trading on December 17, when the company announced disappointing mid-stage trial results with TC-5619, leading the company to drop further development of the investigational compound for schizophrenia or Alzheimer’s disease. 17 December 2013
Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD) market is expected to decline from $3.4 billion in 2012 to $2.9 billion by 2019, at a negative compound annual growth rate (CAGR) of 2.3%, says a new report from business intelligence provider GBI Research. 17 December 2013
French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study of Dysport (abobotulinumtoxin A) in adult upper limb spasticity. 17 December 2013
In a third take-over deal announced this year, USA-based specialty health care company Endo Health Solutions says it has entered into a definitive agreement to acquire NuPathe for $2.85 per share in cash, or around $105 million. 16 December 2013
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded domestic formulations business of fellow Indian drugmaker Elder Pharmaceuticals for around 20 billion rupees (about $325 million). 13 December 2013
In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire privately-held Kyalin Biosciences, an early-stage company based in San Diego, California, that is developing therapies targeting the core symptoms of autism and related conditions. 13 December 2013
Biotech firm Prothena has entered into a worldwide collaboration with Swiss drug major Roche to develop and commercialize antibodies that target alpha-synuclein. 12 December 2013